PROGRESS REPORT FOR:
Food and Drug Safety
ON SEPTEMBER 26, 1995, the Public Health Service (PHS) conducted a review of
progress on Healthy People 2000 objectives in the Food and Drug Safety priority area. The
Food and Drug Administration (FDA) is the designated PHS lead agency for the Food and Drug
Safety priority area. The Deputy Administrator of the U.S. Department of Agriculture's
(USDA) Food Safety and Inspection Service (FSIS) participated in the Progress Review. The
National Institutes of Health (NIH), Indian Health Service (IHS), Centers for Disease
Control and Prevention (CDC), Agency for Healthcare Research and Quality (AHRQ), and
Health Care Financing Administration (HCFA) were also represented. Guests included the
American Medical Association, American Nurses Association, Conference for Food Protection,
National Council on Patient Information and Education, and National Association of Boards
of Pharmacy.
The progress review focused attention on the importance of FDA's Hazard Analysis
Critical Control Point (HACCP) approach to food safety and efforts underway to make this
food safety system standard in the U.S. food supply. HACCP employs a science-based
analysis of potential hazards, determining where problems can occur and instituting
measures to prevent or correct such occurrences.
Objectives 12.1-4 relate to reducing the incidence of foodborne illnesses, encouraging
safe food preparation practices, and extending the adoption of model food codes. As
reported in the April 12, 1995, issue of the Journal of the American Medical Association,
there was a reduction in the observed incidence of listeriosis between 1989 and 1993,
largely as a result of industry, regulatory, and educational efforts conducted by public
and private sector organizations working together. Replication of this success for other
pathogens may not be possible, owing to the changing epidemiology of foodborne diseases,
increased consumer demand for fresh foods year-round, and the appearance of emerging
pathogens in new products. In addition, current surveillance systems may not be able to
detect changes in incidence. For example, not all States require the reporting of E. coli
0157 and Campylobacter infections. A decreasing trend in the number of Salmonella
enteritidis outbreaks has also been detected and may be associated with the adoption of
quality assurance programs by egg producers. Because the elderly and the immunocompromised
are more susceptible to salmonellosis, FDA has worked with HCFA to encourage safe food
preparation practices and the use of pasteurized eggs in nursing homes.
FDA and USDA/FSIS issued regulatory proposals that would require seafood processing
plants and federally inspected meat and poultry plants to adopt HACCP systems for
documenting production of safe products. FDA has approved irradiation for use with poultry
products. A petition for use of irradiation in other meat products is now under review.
On the basis of a Memorandum of Understanding between FDA and the Conference for Food
Protection, the Food Code is being reviewed by the Conference. FDA plans to revise the
Food Code every 2 years. To promote adoption of the Code by States and professional and
trade groups, FDA initiated regional training programs in 1994, made presentations before
more than 50 audiences that year and, with USDA, conducted four video satellite
teleconferences directed at State and local officials. To assist in implementing the Code,
the agency has completed development of its Electronic Inspection System (EIS), which
provides findings to food establishment operators more efficiently. The IHS representative
noted that the incidence of gastrointestinal illnesses had declined by 81 percent since
1974 among American Indians and Alaskan Natives, reflecting to a large degree the success
of educational efforts directed at foodhandlers.
Participants in the Progress Review then turned to drug safety issues. It was noted
that 98 percent of all pharmacies are now computerized and have the capacity to be linked
to centralized databases. Efforts to implement computerized patient records and potential
impacts that this technological advance will have on the interaction between health
professionals and their patients were discussed.
Objective 12.6 was expanded in the 1995 Midcourse Review to include drug profile
reviews by dispensers of medication. In 1992, the Primary Care Providers Survey indicated
that 84 percent of internists and 70 percent of family physicians surveyed maintained a
current medication list for 81-100 percent of their patients 65 and older. A survey
conducted in 1993 by the National Association of Retail Druggists, while not specifically
focusing on the age group targeted in Objective 12.6, showed that 92 percent of
pharmacists queried reported that they provided printed patient drug information. A 1994
study by the National Association of Boards of Pharmacy found that 64 percent of consumers
stated that they had received printed material about their medications from the pharmacy.
While it was acknowledged that this upward trend in pharmacy-provided information may be
due in part to implementation of requirements of the Omnibus Budget Reconciliation Act of
1990, representatives for the profession of pharmacy stressed that this observation is
consistent with current shifts in the practice of pharmacy toward a concept of patient
advocacy and total care.
In 1993, the FDA MedWatch program was launched to inform health professionals about the
importance of monitoring for adverse events and product problems and to facilitate
voluntary reporting of such events directly to the agency. The FDA Desk Guide for Adverse
Event and Product Problem Reporting, which contains reporting forms and instructions for
health professionals, can be requested by calling 1-800-FDA-1088. There was an initial
mailing of the Desk Guide to approximately one-half of all internists in the United States
during 1993. The MedWatch reporting form has been published in many widely used drug
information sources, such as the Physicians' Desk Reference, American Medical Association
(AMA) Drug Evaluations, and U.S. Pharmacopoeia Dispensing Information. For 1994, FDA
estimates that 71.6 percent of the adverse drug event reports received by the agency were
interpreted as serious. FDA reported that over 100 organizations representing both health
professionals and industry have joined as partners to promote the effective use of the
MedWatch program. The discussion focused on the need to ensure the consistent quality and
usefulness of printed information being provided to patients concerning the medications
they take. It was noted that AHRQ has an initiative in progress designed to acquaint
beneficiaries with the types and scope of information they should expect to receive during
encounters with physicians and pharmacists. AHRQ noted that we are faced with a
significant technical challenge by the increasing need to share information about patients
while preserving the patient's right to confidentiality.
The progress review concluded with a call for greater efforts in the areas of both
consumer and provider education. There is, as well, a need to strengthen collaboration
among Federal agencies (Administration on Aging, for example) and between the Federal
sector and professional and patient organizations. Several issues could be brought into
sharper focus by research, including how information provided to patients can lead to
better health outcomes.
Back to Progress Review Page